THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 11:59 pm (Eastern Time) on October 24, 2024, a ...

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of Autonomix, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October ...

THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced it has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum taking place on October 8-9, 2024 in Irvine, California. The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of l ...

Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human clinical trial THE WOODLANDS, TX, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced its technology and interim clinical trial findings will be featured in a pod ...

神经系统疾病治疗技术平台 - 公司正在开发用于感知和治疗神经系统疾病的创新技术平台[137] - 公司的首个产品针对胰腺癌患者的疼痛进行治疗，但该技术平台有潜力应用于多种神经系统疾病[138] - 公司的感知导管已在动物模型中成功识别特定神经信号并确认治疗后信号终止[140] - 公司正准备进行首次人体试验以缓解胰腺癌相关疼痛，并计划将感知和治疗技术结合进行关键性临床试验[140] 许可协议 - 公司于2024年7月与RF Innovations公司签订许可协议,获得其Apex 6射频消融发生器的非独家许可[141] 研发费用 - 2024年第二季度,公司的研发费用同比增加159%至95.4万美元,主要用于临床试验计划和开发[144] 融资需求 - 公司预计需要额外融资约4000万美元来完成临床试验并推进产品商业化[149] - 公司目前的现金储备预计可维持运营至2025年第二季度[147] 员工补偿 - 公司已与关键员工签订协议,一旦被终止将获得1.1-1.6百万美元的补偿[154]

财务业绩 - 2025财年第一季度收入为[数据未提供][1] - 公司对未来业绩前景和指引未提供具体信息[1] 运营亮点 - 公司在2024年6月30日结束的2025财年第一季度公布了财务业绩和最新运营亮点[10] - 用户数据方面未提供具体数字[1] 新发展 - 新产品和新技术研发、市场扩张和并购、其他新策略等方面未提及[1]

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Of ...

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Of ...